Publications by Robert Jones on tumour destruction using Phenergan® to disrupt energy metabolism of cancer cells.
This article is for interest only and should not form the basis of diagnosis or treatment of any medical condition or illness. If you are unwell or have a specific medical condition, please base your healthcare decisions on the advice of a medical doctor or other healthcare practitioner.
Jones GRN. Cancer: restriction of chemical energy by fatty acids as the common pathway whereby various anti-tumour procedures selectively damage malignant cells in situ. Med Hypoth 1976; 2: 50-54.
Jones GRN. Cancer: energy uncoupling as a primary event in endotoxin-induced necrosis of the S180 sarcoma in situ. Biochem Soc Trans 1977; 5: 214-16.
Jones GRN. The selective induction of cellular damage within neoplasia in situ: a putative role for sympathomimetic agents. Med Hypoth 1976; 3: 215-16.
Jones GRN, Winter H, Merkel R. Alterations in the adenine nucleotide pattern as a sensitive means of assessing injury in a solid tumour. Hoppe-Seiler Zeits Physiol Chemie 1978; 359: 1102-103.
Jones GRN, Hummel J, Mahr J, Merkel R. Interference with energy production in the S180 sarcoma caused by isoproterenol and endotoxin. Naunyn-Schmiedeberg Arch Pharmacol 1979; 307 (Supplement): R18.
Jones GRN. Early mitochondrial damage in the induction of haemorrhagic necrosis in the Crocker sarcoma (S180) by endotoxin. J Cancer Res Clin Oncol 1979; 93: 245-54.
Jones GRN. Early cutback in chemical energy production in the Crocker sarcoma (S180) undergoing haemorrhagic necrosis as a result of endotoxin administration. J Cancer Res Clin Oncol 1980; 96: 53-64.
Jones GRN, Baum R, Merkel R, Schwarz M. Disturbance in vivo to energy production caused by hormones and sympathomimetics in the S180 sarcoma, with consequent drug-induced necrosis. Biochem Soc Trans 1980; 8: 105.
Jones GRN. Prevention of drug-induced upset to energy production in the S180 sarcoma by inhibition of prostaglandin synthetase. Biochem Soc Trans 1980; 8: 106-107.
Jones GRN, Ellis, R, Frohn MJN. Drug-induced interference with energy metabolism in the S180 sarcoma: a new principle in the production of selective tumour injury. Oncodev Biol Med 1981; 2: 155-64.
Jones GRN. A new approach to the selectivity of anti-tumour action. Brit J Cancer 1982; 45: 638.
Jones GRN, Miller S, Scobie-Trumper P. Resensitization of drug-resistant S180 tumour cells with ergotamine. Biochem Soc Trans 1982; 10: 502-503.
Jones GRN. Interference with energy production as a means of causing injury to a human pancreatic carcinoma. Oncology 1983; 40: 259-62.
Jones GRN, Frohn MJN. An injurious effect of chlorpromazine in the murine S180 sarcoma (var CB) and its relevance to cancer treatment. Biochem Soc Trans 1984; 12: 679-80.
Jones GRN, Frohn MJN, Beckett AH. Liminal therapy: a strategy for the complete and selective destruction of malignant tissue in situ. Med Hypoth 1984; 15: 349-59.
Jones GRN, Thatcher R. A comparison of the effects of the optical isomers of isoproterenol on energy metabolism in a mouse sarcoma. Experientia 1985; 41: 1045-46.
Jones GRN. Cancer therapy: phenothiazines in an unexpected role. Tumori 1985; 71: 563-69.
18. Jones GRN. Free radicals in immunological killing: the case for tumour necrosis factor (TNF). Med Hypoth 1986; 21: 267-71.
Jones GRN. Cancer therapy at the crossroads: which direction for the future? Physiol Chem Phys Med NMR 1991; 23: 217-20.
Jones GRN. Cancer destruction in vivo through disrupted energy metabolism. I. The endogenous mechanism of self-destruction within the malignant cell, and the roles of endotoxin, certain hormones and drugs, and active oxygen in causing cellular injury and death. Physiol Chem Phys Med NMR 1992; 24: 169-79.
Jones GRN. Cancer destruction in vivo through disrupted energy metabolism. II. Lipid peroxidation and cell death: drug resistance as a consequence of reversible cellular injury. Physiol Chem Phys Med NMR 1992; 24: 181-94.
Jones GRN. Cancer destruction in vivo through disrupted energy metabolism. III. Spontaneous drug resistance, selectivity of antineoplastic action, and strategies for intensifying tumour injury. Physiol Chem Phys Med NMR 1992; 24: 195-212.
Jones GRN. Successful cancer therapy with promethazine: the rationale. Med Hypoth 1996; 46: 25-29.
Jones GRN. Coagulative necrosis: the forgotten way to die. Biochem Soc Trans 1998; 26: S321.
- Jones GRN. Treatment of cancer with low-dose phenothiazines, with special reference to promethazine. In: Non-Antibiotics: a new class of unrecognised antimicrobics (eds Chakrabarty AN, Molnar J, Dastidar SG) pp.79-93. Nat Sci Science Comm (NISCOM), New Delhi, India (1998).
Copyright © 2008 Robert Jones